Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use

Journal of Chemotherapy

Volumn 22, Issue 3, 2010, Pages 175-178

  Daikos, George L ^a   Skiada, A ^a   Pavleas, J ^b   Vafiadi, C ^c   Salatas, K ^b   Tofas, P ^a   Tzanetou, K ^a   Markogiannakis, A ^b   Thomopoulos, G ^b   Vafiadi, I ^a   Petrikkos, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Colistin; Dosing regimens; Pseudomonas aeruginosa; Serum bactericidal activity

Indexed keywords

COLISTIMETHATE;

ADULT; AGED; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PSEUDOMONAS AERUGINOSA; SERUM;

EID: 78650245529     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.3.175     Document Type: Article

References (16)

1. Giske CG, Monnet DL, Cars O, Carmelli Y on hehalf of React-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli Antimicrob Agents Chemother 2008; 52: 813-821.
2. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341. (Pubitemid 40570245)
3. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2001; 6:589-601.
4. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez JJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003; 36: 1111-1118. (Pubitemid 36549630)
5. Levin AS, Barone A, Pençco J et al. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-1011. (Pubitemid 29203530)
6. Kroeger LA, Howde LB, Mitropoulos I, Schafer J, Rottschafer JC. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3431-3433. (Pubitemid 350067572)
7. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-992. (Pubitemid 38008420)
8. Li J, Turnidge JD, Milne RW, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-785.
9. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Therapeut 2008; 30:144-151.
10. Li J, Milne RW, Nation RL, Turnidge JD, Coulthhard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid- phase extraction cartridges and reversed-phase high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl 2001; 761:167-175. (Pubitemid 32817106)
11. Li J, Milne RW, Nation RL, Turnidge JD, Coulthhard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002; 46: 3304-3307.
12. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthhard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008; 61: 636-642. (Pubitemid 351321139)
13. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 2009; 53: 3430-6.
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12. (Pubitemid 28068148)
15. Wallace SJ, Li J, Nation RL et al. Subacute toxicity of colistin methane-sulfonate in rats: comparison of various intravenous dosing regimens. Antimicrob Agents Chemother 2008; 52:1159-61. (Pubitemid 351358406)
16. Hakim A, Kallel H, Sahnoun Z et al. Lack of nephrotoxicity following 15-day therapy with high doses of colistin in rats. Med Sci Monit 2008; 14: BR74-77.